CA
NZ
UK
AU
IND
US
Joseph C. Ventura, an officer of Humana Inc., filed a Form 144 notice on November 9, 2026, disclosing a proposed sale of 5,495 shares of Humana common stock through Goldman Sachs on the New York Stock Exchange.
Robin Energy Ltd. filed a Form 6-K with the U.S. Securities and Exchange Commission on November 9, 2026, disclosing that its Board of Directors has determined to effect a one-for-seventy five (1-for-75) reverse stock split of the company's common shares.
Morgan Stanley Finance LLC filed a free writing prospectus on November 9, 2026, for Principal at Risk Securities linked to NVIDIA Corporation common stock, with an automatic call feature and contingent coupon with memory, maturing November 15, 2027.
Morgan Stanley Finance LLC filed a free writing prospectus on November 9, 2026, for Market Linked Securities (Preliminary Pricing Supplement No. 19,955) linked to the lowest performing of three equity indexes, with an expected maturity of November 23, 2029.
Werewolf Therapeutics, Inc. filed a Form 8-K with the SEC on November 9, 2026, disclosing new clinical data from its Phase 1/1b trial of WTX-124 and its Phase 1b/2 trial of WTX-330 for the treatment of solid tumors.
Surgery Partners, Inc. filed a current report on November 9, 2026, disclosing that on November 8, 2026, it entered into Amendment No. 1 to its Agreement and Plan of Merger with Spyglass Topco, LLC, Spyglass Merger Subsidiary, Inc., and guarantor Bon Secours Mercy Health, …
James M. Langrock, Chief Financial Officer and SVP of 1 800 Flowers Com Inc, filed a Form 4 on November 9, 2026, disclosing a share withholding transaction on November 5, 2026, related to the vesting of restricted stock.
Illumina, Inc. issued a press release on November 9, 2026, announcing an early access program for a new ultrasensitive duplex sequencing workflow designed to detect circulating tumor DNA in plasma samples for molecular residual disease research.
Nkarta, Inc. filed an 8-K on November 9, 2026, disclosing initial clinical data from its Phase 1/2 Ntrust-2 basket study and integrated safety data from its Ntrust-1 and Ntrust-2 trials evaluating NKX019 in myositis and systemic sclerosis, presented at ACR Convergence 2026.
Citigroup Global Markets Holdings Inc. filed a free writing prospectus on November 9, 2026, disclosing preliminary terms for 6-Year Buffer Securities linked to the S&P 500 Index, with a pricing date of November 23, 2026, and maturity on November 29, 2032.
Please wait processing your request...